Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance

Journal of Pathology

Volumn 188, Issue 4, 1999, Pages 351-360

  Brambilla, Elisabeth ^a,b,c   Moro, Denis ^a   Gazzeri, Sylvie ^a   Brambilla, Christian ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL MICHALLON   (France)

^c Laboratoire de Pathologie Cellulaire   (France)

Author keywords

Basaloid carcinoma; Cyclin D1; Immunohistochemistry; Lung cancer; p16(INK4A); Prognosis; Retinoblastoma protein

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032786446     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W     Document Type: Article

References (44)

1. Minna JD, Sekido Y, Fong K, Gazdar AF. Molecular biology of lung cancer. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott, 1997; 849-857.
2. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
3. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85: 27-37.
4. Michalides RJ, Van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55: 975-978.
5. Gillet C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-1817.
6. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995; 10: 775-778.
7. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
8. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibitor by the tumor suppressor p16. Nature 1995; 375: 503-506.
9. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995; 55: 6006-6011.
10. INK4 protein is restricted to the subset of lung cancer lines that retains wild-type RB. Oncogene 1994; 9: 3375-3378.
11. INK4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55: 505-509.
12. INK4 in human cancer. Proc Natl Acad Sci U S A 1994; 91: 11 045-11 049.
13. INK4a expression in resected non-small cell lung tumors. Cancer Res 1996; 56: 3415-3420.
14. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996; 65: 442-445.
15. Schauer IE, Siriwardana S, Langan TA, Sclafani RA. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A 1994; 91: 7827-7831.
16. INK4A inactivation in non small-cell lung cancers. Oncogene 1998; 16: 497-505.
17. Alle KM, Henshall SM, Field AS, Sutherland RL. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998; 4: 847-854.
18. Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognosis significance. Hum Pathol 1992; 23: 993-1003.
19. Moro D, Brichon PY, Brambilla E, Veale D, Labat-Moleur F, Brambilla C. Basaloid bronchial carcinoma. A histological group with a poor prognosis. Cancer 1994; 73: 2734-2739.
20. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, in collaboration with LH Sobin and Pathologists from 14 countries. Histological Typing of Lung and Pleural Tumors, 3rd edn. World Health Organization: International Histological Classification of Tumors. Heidelberg: Springer, 1999.
21. Gouyer V, Gazzeri S, Brambilla E, et al. Loss of heterozygosity at the Rb locus in primary malignant neuroendocrine lung carcinomas. Int J Cancer 1994; 58: 818-824.
22. Xu HJ, Hu SX, Cagle PT, Moore GE, Benedict WF. Absence of retinoblastoma protein expression in primary non small cell lung carcinomas. Cancer Res 1991; 51: 2735-2739.
23. Reissmann PT, Koga H, Takahashi R, et al. Inactivation of the retinoblastoma susceptibility gene in non small cell lung cancer. Oncogene 1993; 8: 1913-1919.
24. Dosaka-Akita H, Hu SX, Fujino M, Harada M, Kinoshita I, Xu HJ. Altered retinoblastoma protein expression in non-small cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 1997; 79: 1329-1337.
25. INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 1996; 56: 5557-5562.
26. Mate JL, Ariza A, Aracil C, Lopez D, Isamat M, Perez-Piteira J. Cyclin D1 overexpression in non-small cell lung cancer carcinoma: correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol 1996; 180: 395-399.
27. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small cell lung cancer. Br J Cancer 1996; 73: 294-300.
28. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 1997; 3: 1051-1058.
29. Xu HJ, Quinlan DC, Davidson AG, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small cell lung carcinoma. J Natl Cancer Inst 1994; 86: 695-699.
30. Xu HJ, Cagle PT, Hu SX, Li J, Benedict WF. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. Clin Cancer Res 1996; 2: 1169-1176.
31. INK4 expression in non-small cell lung carcinoma. Cancer 1997; 80: 389-395.
32. Parry D, Bates S, Mann DJ, Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 1995; 14: 503-511.
33. Shimizu E, Coxon A, Otterson GA, et al. Rb protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 1994; 9: 2441-2448.
34. Van Diest PJ, Michalides RJA, Jannink I, et al. Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am J Pathol 1997; 150: 705-711.
35. Kotelnikov V, Coon JS IV, Mundle S, et al. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 1997; 3: 95-101.
36. Sofer-Levi Y, Resnitzky D. Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E. Oncogene 1996; 13: 2431-2437.
37. Kranenburg O, van der Eb AJ, Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 1996; 15: 46-54.
38. kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ 1996; 7: 699-710.
39. Haas-Kogan DA, Kogan SC, Levi D, Dazin P, T'Ang ?, Fung YK. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995; 14: 461-472.
40. Wang J, Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 1996; 273: 359-360.
41. Bellacosa A, Almadori G, Cavallo S, et al. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 1996; 2: 175-180.
42. Takeuchi H, Ozawa S, Ando N, et al. Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 1997; 3: 2229-2236.
43. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995; 146: 1161-1169.
44. Seshadri R, Lee CSL, Hui R, McCaul K, Horsfall DJ, Sutherland RL. Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 1996; 2: 1177-1184.